LRRTM2

LRRTM2 is a postsynaptic leucine-rich repeat transmembrane protein that functions as a trans-synaptic organizer of excitatory synapses by binding presynaptic neurexins and positioning AMPA receptors within synaptic nanocolumns. It selectively binds α- and β-neurexins lacking a splice-site 4 insert through its concave LRR surface, and this interaction induces presynaptic differentiation and is required for LTP and AMPA receptor-mediated transmission but not NMDA receptor-mediated transmission (PMID:20064387, PMID:20064388, PMID:29784826). Acute severing of the LRRTM2 extracellular domain rapidly declusters AMPARs from presynaptic release sites, reducing evoked but not spontaneous transmission, demonstrating that LRRTM2 acutely controls synaptic strength by positioning receptors within nanocolumns independently of total receptor number (PMID:34417170). Its intracellular C-terminal YxxC and PDZ-binding motifs govern synaptic confinement and surface dynamics, while its transcription is induced by nuclear calcium/CaMKIV–CREB signaling downstream of synaptic NMDA receptor activation (PMID:34498765, PMID:25527504).

1. 2009 High

   Identification of neurexins as the presynaptic binding partner of LRRTM2 established it as a trans-synaptic adhesion molecule that induces excitatory presynaptic differentiation and revealed a splice-code: LRRTM2 selectively binds neurexins lacking splice-site 4 inserts.

   Evidence Affinity chromatography, shRNA epistasis, cell-adhesion junction assays, and splice-variant binding assays in two independent studies

   PMID:20064387 PMID:20064388

   Open questions at the time

   • Structural basis of neurexin–LRRTM2 interaction unknown
   • Whether LRRTM2 has postsynaptic roles beyond synapse number not tested
   • In vivo loss-of-function phenotype not established
2. 2014 Medium

   Demonstrating that Lrrtm2 transcription is driven by nuclear calcium/CaMKIV–CREB/CBP signaling downstream of synaptic NMDA receptor activation established LRRTM2 as an activity-regulated synapse organizer, linking synaptic activity to structural synapse remodeling.

   Evidence Promoter reporter assays, pharmacological inhibition of CaMKs and NMDA receptors, nuclear calcium buffering in hippocampal neurons

   PMID:25527504

   Open questions at the time

   • Regulation shown at promoter/mRNA level; activity-dependent changes in LRRTM2 protein levels not demonstrated
   • Functional consequences of activity-induced LRRTM2 upregulation on synaptic strength not tested
3. 2016 High

   Solving the LRRTM2 crystal structure identified the concave LRR surface as the neurexin-binding interface and provided quantitative binding affinities, establishing the structural framework for understanding trans-synaptic adhesion specificity.

   Evidence X-ray crystallography of thermostabilized mouse LRRTM2, binding affinity measurements with neurexin-β1 ± Ca²⁺, cell-based synapse formation assay

   PMID:26785044

   Open questions at the time

   • Co-crystal structure of LRRTM2–neurexin complex not obtained
   • Contribution of individual LRR residues to binding and synaptogenesis not mapped
4. 2018 High

   Conditional knockout of LRRTM1/2 revealed that these proteins are required for LTP and selectively maintain AMPA receptor-mediated (not NMDA receptor-mediated) transmission, with the extracellular neurexin-binding domain being necessary and sufficient for LTP rescue, establishing a postsynaptic signaling role beyond synapse formation.

   Evidence Conditional KO in CA1 neurons, electrophysiology, domain-deletion rescue, photoactivatable GluA1 live imaging

   PMID:29784826

   Open questions at the time

   • Individual contributions of LRRTM1 vs LRRTM2 not resolved (double KO used)
   • Mechanism by which the extracellular domain stabilizes AMPARs at spines not defined
5. 2019 Medium

   Showing that LRRTM2 synaptogenic activity is independent of N-cadherin distinguished its mechanism from that of Neuroligin-1, which requires N-cadherin, indicating mechanistically distinct trans-synaptic signaling pathways despite shared neurexin binding.

   Evidence N-cadherin knockdown/blocking in cultured cortical neurons with immunostaining for presynaptic markers

   PMID:31780894

   Open questions at the time

   • Downstream presynaptic signaling pathway activated by LRRTM2 not identified
   • Result limited to cultured cortical neurons; in vivo epistasis not tested
6. 2021 High

   Acute proteolytic removal of the LRRTM2 extracellular domain demonstrated that LRRTM2 acutely positions AMPARs within trans-synaptic nanocolumns to control evoked transmission, separating its role in receptor positioning from its role in total receptor number.

   Evidence Engineered rapid proteolysis, super-resolution imaging, and evoked vs. spontaneous EPSC electrophysiology

   PMID:34417170

   Open questions at the time

   • Identity of presynaptic nanocolumn partners organized by LRRTM2 not fully resolved
   • Whether other LRRTMs can substitute for nanocolumn organization not tested
7. 2021 Medium

   Dissection of the intracellular domain revealed that a YxxC motif (not the PDZ-binding ECEV motif) is the primary determinant of LRRTM2 synaptic confinement, while both motifs contribute to nanoscale organization, identifying the molecular determinants of postsynaptic anchoring.

   Evidence C-terminal deletion/point mutants, single-molecule tracking, dSTORM super-resolution microscopy

   PMID:34498765

   Open questions at the time

   • Binding partner of the YxxC motif not identified
   • How intracellular motifs coordinate with the extracellular domain to organize nanocolumns not determined
8. 2024 High

   Domain-specific mutant analysis in conditional KO mice unified the model: the N-terminal neurexin-binding interface controls both presynaptic nano-organization and postsynaptic AMPAR sub-positioning, while C-terminal motifs control LRRTM2's own surface expression and synaptic clustering.

   Evidence Conditional KO, domain-deletion/point mutants targeting the neurexin-binding C-terminal LRR cap, super-resolution imaging, electrophysiology

   PMID:39394199

   Open questions at the time

   • Whether the neurexin-binding interface acts solely through neurexin or additional cis/trans partners contribute remains untested
   • In vivo behavioral consequences of domain-specific mutations not assessed
9. 2025 Medium

   Endogenous tagging via CRISPR showed LRRTM2 is present at ~80% of excitatory synapses and its levels correlate with PSD-95 and AMPAR content, but C-terminal mutations that increase synaptic LRRTM2 do not proportionally increase AMPARs, dissociating LRRTM2 accumulation from AMPAR recruitment.

   Evidence Two-guide CRISPR whole-CDS knock-in for endogenous tagging, quantitative fluorescence imaging, C-terminal domain point mutations

   PMID:39824639

   Open questions at the time

   • Mechanism by which LRRTM2 recruits AMPARs (direct binding vs. scaffold intermediates) not resolved
   • Findings from single lab; independent replication needed

• Key open questions include the identity of the intracellular YxxC-motif binding partner, the structural basis of the neurexin–LRRTM2 complex, and the mechanism by which extracellular neurexin binding is transduced into postsynaptic AMPAR positioning and stabilization.
• No co-crystal structure of neurexin–LRRTM2 complex exists
• The intracellular binding partner of the YxxC motif is unknown
• How LRRTM2's extracellular domain mechanistically couples to AMPAR stabilization machinery remains unresolved